With the broader effects of leronlimab compared to tolcilizumab there will be a faster resolution. The cases where you're more likely to see mortality past 28 days would be the very critical cases who may have went into organ failure very shortly after receiving leronlimab. 28 days vs. 42 days might be near equal when it comes to affect it has on the p value.